We explore the depths of the brain to develop solutions for neurological conditions that impact millions of people worldwide. This constant driver of innovation enables us to charter new paths to life-transforming treatments.
APTIOM® (eslicarbazepine acetate) is indicated as:
- Monotherapy in the management of partial-onset seizures in adult patients with epilepsy. All patients who participated in the monotherapy trial were newly or recently diagnosed with epilepsy
- Adjunctive therapy in the management of adults, and children above 6 years of age, with partial-onset seizures who are not satisfactorily controlled with conventional therapy.